- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Stephen Heitner Outlines the Next Steps After MAVERICK-HCM Study Findings
Based off the rich data available on mavacamten efficacy within subsets of patients with non-obstructive HCM, researchers have designed the next phase of study on this select group, said Stephen Heitner, MD, director of Clinical Trials and director of the Hypertrophic Cardiomyopathy Center at the Oregon Health and Science University.
Based off the rich data available on mavacamten efficacy within subsets of patients with non-obstructive HCM, researchers have designed the next phase of study on this select group, said Stephen Heitner, MD, director of Clinical Trials and director of the Hypertrophic Cardiomyopathy Center at the Oregon Health and Science University.
Transcript
Can you discuss the results from MAVERICK-HCM? How will the insights from this study drive the next phase of research in non-obstructive HCM?
MAVERICK—we’re super excited to have finished. That’s looking at, I think there were 59 patients in this placebo-controlled multi-site study, looking at the impact of mavacamten in patients with non-obstructive HCM. You know this is a very ... challenging group of patients. What we have seen–you know this is a very high-level result–is firstly, that the NT-proBNP, which is a measure of left ventricular filling–a lot of these patients have heart failure with preserved ejection fraction as a result of hypertrophic cardiomyopathy. So, their NT-proBNPs was significantly reduced after 16 weeks of mavacamten therapy, which is incredible. What we’re doing right now is kind of going through the very rich data that we have from that to look at where mavacamten will be most useful. So, which subset of those patients mavacamten will be applicable for. Based on that, we’re going to be designing the next phase of study, which is the phase 3 in non-obstructive HCM patients to better inform and hopefully show that this is an effective therapy in these individuals.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
